China In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

News provided by

Jan 10, 2012, 04:17 ET

NEW YORK, Jan. 10, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

China In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

http://www.reportlinker.com/p0750101/China-In-Vitro-Diagnostics-Market-Outlook-to-2017--Clinical-Chemistry-Genetic-Testing-Haematology-Histology-and-Cytology-Immuno-Chemistry-Infectious-Immunology-and-Microbiology-Culture.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

China In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Summary

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

- Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.- Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2003 to 2010, forecast forward for 7 years to 2017. - 2010 company shares and distribution shares data for each of the seven market categories.- Global corporate-level profiles of key companies operating within the China In Vitro Diagnosticsmarket. - Key players covered include Siemens Healthcare, F. Hoffmann-La Roche Ltd., Sysmex Corporation, Abbott Laboratories, Mindray Medical International Limited, Ortho-Clinical Diagnostics Inc. and others.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.- Develop market-entry and market expansion strategies.- Design competition strategies by identifying who-stands-where in the China In Vitro Diagnostics competitive landscape.- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.- What are the key distribution channels and what's the most preferred mode of product distribution – Identify, understand and capitalize.1 Table of Contents1 Table of Contents 21.1 List of Tables 91.2 List of Figures 122 Introduction 152.1 What is This Report About? 153 In Vitro Diagnostics In China 163.1 In Vitro Diagnostics, Market Segmentation 163.2 In Vitro Diagnostics, China, Overall Revenue ($m), USD Actual, 2003-2017 173.3 In Vitro Diagnostics Market, China, Revenue Mix ($m), 2010 193.4 In Vitro Diagnostics Market, China, Category Contribution (%), 2010 203.5 In Vitro Diagnostics, China, Company share (2009-2010) 274 Clinical Chemistry In China 294.1 Clinical Chemistry, Market Segmentation 294.2 Clinical Chemistry Market, China, Revenue Mix ($m), 2010 304.3 Clinical Chemistry Market, China, Segment Contribution (%), 2010 314.4 Clinical Chemistry Overall Revenue (2003-2017) 324.4.1 Clinical Chemisty Analyzers Revenue (2003-2017) 364.4.2 Urine Analysis Revenue (2003-2017) 404.5 Clinical Chemistry Distribution Share (2009-2010) 444.6 Clinical Chemistry, China, Company share (2009-2010) 455 Genetic Testing In China 475.1 Genetic Testing, Market Segmentation 475.2 Genetic Testing Market, China, Revenue Mix ($m), 2010 485.3 Genetic Testing Market, China, Segment Contribution (%), 2010 495.4 Genetic Testing Overall Revenue (2003-2017) 505.5 Genetic Testing Distribution Share (2009-2010) 545.6 Genetic Testing, China, Company share (2009-2010) 556 Haematology In China 576.1 Haematology, Market Segmentation 576.2 Haematology Market, China, Revenue Mix ($m), 2010 586.3 Haematology Market, China, Segment Contribution (%), 2010 596.4 Haematology Overall Revenue (2003-2017) 606.4.1 Haematology Reagents Revenue (2003-2017) 646.4.2 Immunohaematology Revenue (2003-2017) 686.4.3 Haemostasis Revenue (2003-2017) 726.4.4 Haematology Rapid Tests Revenue (2003-2017) 766.4.5 Haematology Cell Counters Revenue (2003-2017) 806.5 Haematology Distribution Share (2009-2010) 846.6 Haematology, China, Company share (2009-2010) 857 Histology And Cytology In China 877.1 Histology And Cytology, Market Segmentation 877.2 Histology And Cytology Market, China, Revenue Mix ($m), 2010 887.3 Histology And Cytology Market, China, Segment Contribution (%), 2010 897.4 Histology And Cytology Overall Revenue (2003-2017) 907.5 Histology And Cytology Distribution Share (2009-2010) 947.6 Histology And Cytology, China, Company share (2009-2010) 958 Immuno Chemistry In China 978.1 Immuno Chemistry Market, China, Revenue Mix ($m), 2010 978.2 Immuno Chemistry Market, China, Segment Contribution (%), 2010 988.3 Immuno Chemistry Overall Revenue (2003-2017) 998.3.1 Disease Specific Immunochemistry Revenue (2003-2017) 1038.3.2 Drugs of Abuse / Toxicology Revenue (2003-2017) 1078.3.3 Endocrinology Tests Revenue (2003-2017) 1118.3.4 Therapeutic Drug Monitoring Revenue (2003-2017) 1158.3.5 Immunochemistry Analyzers Revenue (2003-2017) 1198.4 Immuno Chemistry Distribution Share (2009-2010) 1238.5 Immuno Chemistry, China, Company share (2009-2010) 1249 Infectious Immunology In China 1269.1 Infectious Immunology, Market Segmentation 1269.2 Infectious Immunology Market, China, Revenue Mix ($m), 2010 1279.3 Infectious Immunology Market, China, Segment Contribution (%), 2010 1289.4 Infectious Immunology Overall Revenue (2003-2017) 1299.5 Infectious Immunology Distribution Share (2009-2010) 1339.6 Infectious Immunology, China, Company share (2009-2010) 13410 Microbiology Culture In China 13610.1 Microbiology Culture, Market Segmentation 13610.2 Microbiology Culture Market, China, Revenue Mix ($m), 2010 13710.3 Microbiology Culture Market, China, Segment Contribution (%), 2010 13810.4 Microbiology Culture Overall Revenue (2003-2017) 13910.4.1 Microbiology Analyzers Revenue (2003-2017) 14310.5 Microbiology Culture Distribution Share (2009-2010) 14710.6 Microbiology Culture, China, Company share (2009-2010) 14811 Overview of Key Companies in China In Vitro Diagnostics Market 15011.1 Siemens Healthcare 15011.1.1 Company Overview 15011.1.2 Share in the China In Vitro Diagnostics Market 15011.2 F. Hoffmann-La Roche Ltd. 15111.2.1 Company Overview 15111.2.2 Share in the China In Vitro Diagnostics Market 15111.3 Sysmex Corporation 15211.3.1 Company Overview 15211.3.2 Share in the China In Vitro Diagnostics Market 15211.4 Abbott Laboratories 15311.4.1 Company Overview 15311.4.2 Share in the China In Vitro Diagnostics Market 15311.5 Mindray Medical International Limited 15411.5.1 Company Overview 15411.5.2 Share in the China In Vitro Diagnostics Market 15411.6 Ortho-Clinical Diagnostics Inc. 15511.6.1 Company Overview 15511.6.2 Share in the China In Vitro Diagnostics Market 15511.7 Shanghai Kehua Bio-engineering Co., Ltd. 15611.7.1 Company Overview 15611.8 Beckman Coulter, Inc. 15611.8.1 Company Overview 15611.9 bioMerieux S.A. 15611.9.1 Company Overview 15611.10 Bio-Rad Laboratories, Inc. 15711.10.1 Company Overview 15711.11 Becton, Dickinson and Company 15711.11.1 Company Overview 15711.12 DiaSorin S.p.A 15811.12.1 Company Overview 15811.13 Alere Inc. 15811.13.1 Company Overview 15811.14 Danaher Corporation 15811.14.1 Company Overview 15811.15 Qiagen N.V. 15911.15.1 Company Overview 15911.16 Phadia AB 15911.16.1 Company Overview 15911.17 HORIBA, Ltd. 15911.17.1 Company Overview 15911.18 Nihon Kohden Corporation 16011.18.1 Company Overview 16011.19 Grifols, S.A. 16011.19.1 Company Overview 16011.20 Gen-Probe Incorporated 16111.20.1 Company Overview 16111.21 DIAGNOSTICA STAGO, Inc. 16111.21.1 Company Overview 16111.22 Thermo Fisher Scientific Inc. 16111.22.1 Company Overview 16111.23 PerkinElmer, Inc. 16211.23.1 Company Overview 16211.24 Life Technologies Corporation 16211.24.1 Company Overview 16212 In Vitro Diagnostics Market Pipeline Products 16312.1 Clinical Chemisty Market Pipeline Products 16312.2 Immuno Chemistry Market Pipeline Products 16612.3 Haematology Market Pipeline Products 16912.4 Infectious Immunology Market Pipeline Products 17112.5 Microbiology Culture Market Pipeline Products 17412.6 Histology And Cytology Market Pipeline Products 17512.7 Genetic Testing Market Pipeline Products 17613 Financial Deals Landscape 17913.1 Acquisition 17913.1.1 Mindray Medical International To Acquire Hunan Changsha Tiandiren Biotech 17913.1.2 Mingyuan Medicare Development To Acquire 70% Stake In Shanghai Yuanqi Bio-Pharmaceutical 18013.1.3 Mindray Medical To Acquire Controlling Stake In Suzhou Hyssen Electronics 18113.2 Partnerships 18213.2.1 BioTime Enters Into Distribution Agreement With USCN Life Science 18213.2.2 Rosetta Genomics Enters Into Licensing Agreement With Avatao Biotech 18313.2.3 Sun Yat-sen University Enters Into Co-Development Agreement With BioDesign Institute 18413.2.4 Beijing GP Medical Enters Into Co-Marketing Agreement With Gaoxin Da An 18513.2.5 SuperNova Diagnostics Enters Into An Agreement With Shenzhen Kang Sheng Bao Bio-Technology 18613.2.6 Pacgen Biopharmaceuticals Enters Into Agreement With General Biologicals 18713.2.7 Avacta Group Enters Into Distribution Agreement with Cold Spring Biotech 18814 Recent Developments 18914.1 Strategy And Business Planning 18914.1.1 Dec 13, 2011: China Medical Technologies Intends To Implement Debt Restructuring 18914.1.2 Sep 15, 2011: Covidien Announces R&D Center In China 18914.1.3 Jul 19, 2011: China Sky One Wins Bidding Process On Land Use Rights Covering 19014.1.4 Jun 22, 2011: Johnson & Johnson Opens Innovation Center In China 19014.1.5 Mar 14, 2011: Pacgen Announces Corporate Transformation 19114.1.6 Mar 01, 2011: Thermo Fisher Announces Expansion Plan In China 19114.2 Legal and Regulatory 19214.2.1 Dec 19, 2011: Pomerantz Haudek Files Class Action Against China Medical Technologies 19214.2.2 Apr 11, 2011: Beijing Chaoyang District Court Grants Investigation Letters Against Inverness Medical Beijing 19214.3 Government and Public Interest 19314.3.1 Jan 18, 2011: Mindray Medical To Exhibit At Arab Health 2011 In Dubai 19314.4 Product News 19514.4.1 Nov 01, 2011: Interleukin Genetics Initiates Clinical Studies For PST Genetic Test In Chinese Populations 19514.4.2 Oct 13, 2011: China Medical Receives SFDA Approval For PCR-based KRAS Assay For Colorectal Cancer Targeted Drug 19514.4.3 Aug 10, 2011: China Medical Announces First Inclusion Of FISH Tests For Diagnosis Of Certain Hematological Malignancies In Clinical Guidelines Issued By MOH 19514.4.4 Jul 01, 2011: KHB Launches Automatic Chemistry Analyzer (ZY-1200/ZY-1280) 19614.4.5 Jul 01, 2011: KHB Launches Diagnostic Kit For Hepatitis B Virus YMDD Mutation DNA (Real-Time PCR) 19614.4.6 Apr 28, 2011: Response Biomedical Corporation Receives SFDA Registration Of RAMP 200 19715 Appendix 19815.1 Definitions of Markets Covered in the Report 19915.1.1 In Vitro Diagnostics 19915.2 Research Methodology 21015.3 Secondary Research 21015.4 Primary Research 21115.5 Models 21115.6 Forecasts 21215.7 Expert Panels 21215.8 GlobalData Consulting 21215.9 Currency Conversion 21315.10 Contact Us 21315.11 Disclaimer 213

List of Tables

Table 1: In Vitro Diagnostics, China, Overall Revenue ($m), USD Actual, 2003-2017 18Table 2: In Vitro Diagnostics Market, China, Category Contribution (%), 2010 20Table 3: In Vitro Diagnostics, China, Cross-Category Analysis, 2003-2017 22Table 4: In Vitro Diagnostics, China, Overall Revenue ($m), USD Actual, Historic, 2003-2010 24Table 5: In Vitro Diagnostics, China, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 26Table 6: In Vitro Diagnostics, China, Company share by Revenue ($m), USD Actual, 2009-2010 28Table 7: Clinical Chemistry Market, China, Segment Contribution (%), 2010 31Table 8: Clinical Chemistry, China, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 33Table 9: Clinical Chemistry, China, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 35Table 10: Clinical Chemisty Analyzers, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 37Table 11: Clinical Chemisty Analyzers, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 39Table 12: Urine Analysis, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 41Table 13: Urine Analysis, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 43Table 14: Clinical Chemistry, China, Distribution Share by Revenue ($m), USD Actual, 2009-2010 44Table 15: Clinical Chemistry, China, Company share by Revenue ($m), USD Actual 2009-2010 46Table 16: Genetic Testing Market, China, Segment Contribution (%), 2010 49Table 17: Genetic Testing, China, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 51Table 18: Genetic Testing, China, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 53Table 19: Genetic Testing, China, Distribution Share by Revenue ($m), USD Actual, 2009-2010 54Table 20: Genetic Testing, China, Company share by Revenue ($m), USD Actual 2009-2010 56Table 21: Haematology Market, China, Segment Contribution (%), 2010 59Table 22: Haematology, China, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 61Table 23: Haematology, China, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 63Table 24: Haematology Reagents, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 65Table 25: Haematology Reagents, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 67Table 26: Immunohaematology, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 69Table 27: Immunohaematology, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 71Table 28: Haemostasis, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 73Table 29: Haemostasis, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 75Table 30: Haematology Rapid Tests, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 77Table 31: Haematology Rapid Tests, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 79Table 32: Haematology Cell Counters, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 81Table 33: Haematology Cell Counters, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 83Table 34: Haematology, China, Distribution Share by Revenue ($m), USD Actual, 2009-2010 84Table 35: Haematology, China, Company share by Revenue ($m), USD Actual 2009-2010 86Table 36: Histology And Cytology Market, China, Segment Contribution (%), 2010 89Table 37: Histology And Cytology, China, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 91Table 38: Histology And Cytology, China, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 93Table 39: Histology And Cytology, China, Distribution Share by Revenue ($m), USD Actual, 2009-2010 94Table 40: Histology And Cytology, China, Company share by Revenue ($m), USD Actual 2009-2010 96Table 41: Immuno Chemistry Market, China, Segment Contribution (%), 2010 98Table 42: Immuno Chemistry, China, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 100Table 43: Immuno Chemistry, China, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 102Table 44: Disease Specific Immunochemistry, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 104Table 45: Disease Specific Immuno chemistry, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 106Table 46: Drugs of Abuse / Toxicology, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 108Table 47: Drugs of Abuse / Toxicology, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 110Table 48: Endocrinology Tests, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 112Table 49: Endocrinology Tests, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 114Table 50: Therapeutic Drug Monitoring, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 116Table 51: Therapeutic Drug Monitoring, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 118Table 52: Immunochemistry Analyzers, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 120Table 53: Immunochemistry Analyzers, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 122Table 54: Immuno Chemistry, China, Distribution Share by Revenue ($m), USD Actual, 2009-2010 123Table 55: Immuno Chemistry, China, Company share by Revenue ($m), USD Actual 2009-2010 125Table 56: Infectious Immunology Market, China, Segment Contribution (%), 2010 128Table 57: Infectious Immunology, China, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 130Table 58: Infectious Immunology, China, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 132Table 59: Infectious Immunology, China, Distribution Share by Revenue ($m), USD Actual, 2009-2010 133Table 60: Infectious Immunology, China, Company share by Revenue ($m), USD Actual 2009-2010 135Table 61: Microbiology Culture Market, China, Segment Contribution (%), 2010 138Table 62: Microbiology Culture, China, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 140Table 63: Microbiology Culture, China, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 142Table 64: Microbiology Analyzers, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 144Table 65: Microbiology Analyzers, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 146Table 66: Microbiology Culture, China, Distribution Share by Revenue ($m), USD Actual, 2009-2010 147Table 67: Microbiology Culture, China, Company share by Revenue ($m), USD Actual 2009-2010 149Table 68: Clinical Chemisty Market Pipeline Products 163Table 69: Immuno Chemistry Market Pipeline Products 166Table 70: Haematology Market Pipeline Products 169Table 71: Infectious Immunology Market Pipeline Products 171Table 72: Microbiology Culture Market Pipeline Products 174Table 73: Histology And Cytology Market Pipeline Products 175Table 74: Genetic Testing Market Pipeline Products 176Table 75: Mindray Medical International To Acquire Hunan Changsha Tiandiren Biotech 179Table 76: Mingyuan Medicare Development To Acquire 70% Stake In Shanghai Yuanqi Bio-Pharmaceutical 180Table 77: Mindray Medical To Acquire Controlling Stake In Suzhou Hyssen Electronics 181Table 78: BioTime Enters Into Distribution Agreement With USCN Life Science 182Table 79: Rosetta Genomics Enters Into Licensing Agreement With Avatao Biotech 183Table 80: Sun Yat-sen University Enters Into Co-Development Agreement With BioDesign Institute 184Table 81: Beijing GP Medical Enters Into Co-Marketing Agreement With Gaoxin Da An 185Table 82: SuperNova Diagnostics Enters Into An Agreement With Shenzhen Kang Sheng Bao Bio-Technology 186Table 83: Pacgen Biopharmaceuticals Enters Into Agreement With General Biologicals 187Table 84: Avacta Group Enters Into Distribution Agreement With Cold Spring Biotech 188Table 85: USD to Local Currency, China, Average Actual Rate 2003-2010 213

List of Figures

Figure 1: In Vitro Diagnostics, Market Segmentation 16Figure 2: In Vitro Diagnostics, China, Overall Revenue ($m), USD Actual, 2003-2017 17Figure 3: In Vitro Diagnostics Market, China, Revenue Mix ($m), 2010 19Figure 4: In Vitro Diagnostics Market, China, Category Contribution (%), 2010 20Figure 5: In Vitro Diagnostics, China, Cross-Category Analysis, 2003-2017 21Figure 6: In Vitro Diagnostics, China, Overall Revenue ($m), USD Actual, Historic, 2003-2010 23Figure 7: In Vitro Diagnostics, China, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 25Figure 8: In Vitro Diagnostics, China, Company share (%), 2010 27Figure 9: Clinical Chemistry, Market Segmentation 29Figure 10: Clinical Chemistry Market, China, Revenue Mix ($m), 2010 30Figure 11: Clinical Chemistry Market, China, Segment Contribution (%), 2010 31Figure 12: Clinical Chemistry, China, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 32Figure 13: Clinical Chemistry, China, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 34Figure 14: Clinical Chemisty Analyzers, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 36Figure 15: Clinical Chemisty Analyzers, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 38Figure 16: Urine Analysis, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 40Figure 17: Urine Analysis, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 42Figure 18: Clinical Chemistry, China, Company share (%), 2010 45Figure 19: Genetic Testing, Market Segmentation 47Figure 20: Genetic Testing Market, China, Revenue Mix ($m), 2010 48Figure 21: Genetic Testing Market, China, Segment Contribution (%), 2010 49Figure 22: Genetic Testing, China, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 50Figure 23: Genetic Testing, China, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 52Figure 24: Genetic Testing, China, Company share (%), 2010 55Figure 25: Haematology, Market Segmentation 57Figure 26: Haematology Market, China, Revenue Mix ($m), 2010 58Figure 27: Haematology Market, China, Segment Contribution (%), 2010 59Figure 28: Haematology, China, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 60Figure 29: Haematology, China, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 62Figure 30: Haematology Reagents, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 64Figure 31: Haematology Reagents, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 66Figure 32: Immunohaematology, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 68Figure 33: Immunohaematology, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 70Figure 34: Haemostasis, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 72Figure 35: Haemostasis, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 74Figure 36: Haematology Rapid Tests, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 76Figure 37: Haematology Rapid Tests, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 78Figure 38: Haematology Cell Counters, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 80Figure 39: Haematology Cell Counters, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 82Figure 40: Haematology, China, Company share (%), 2010 85Figure 41: Histology And Cytology, Market Segmentation 87Figure 42: Histology And Cytology Market, China, Revenue Mix ($m), 2010 88Figure 43: Histology And Cytology Market, China, Segment Contribution (%), 2010 89Figure 44: Histology And Cytology, China, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 90Figure 45: Histology And Cytology, China, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 92Figure 46: Histology And Cytology, China, Company share (%), 2010 95Figure 47: Immuno Chemistry Market, China, Revenue Mix ($m), 2010 97Figure 48: Immuno Chemistry Market, China, Segment Contribution (%), 2010 98Figure 49: Immuno Chemistry, China, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 99Figure 50: Immuno Chemistry, China, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 101Figure 51: Disease Specific Immunochemistry, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 103Figure 52: Disease Specific Immuno chemistry, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 105Figure 53: Drugs of Abuse / Toxicology, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 107Figure 54: Drugs of Abuse / Toxicology, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 109Figure 55: Endocrinology Tests, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 111Figure 56: Endocrinology Tests, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 113Figure 57: Therapeutic Drug Monitoring, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 115Figure 58: Therapeutic Drug Monitoring, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 117Figure 59: Immunochemistry Analyzers, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 119Figure 60: Immunochemistry Analyzers, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 121Figure 61: Immuno Chemistry, China, Company share (%), 2010 124Figure 62: Infectious Immunology, Market Segmentation 126Figure 63: Infectious Immunology Market, China, Revenue Mix ($m), 2010 127Figure 64: Infectious Immunology Market, China, Segment Contribution (%), 2010 128Figure 65: Infectious Immunology, China, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 129Figure 66: Infectious Immunology, China, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 131Figure 67: Infectious Immunology, China, Company share (%), 2010 134Figure 68: Microbiology Culture, Market Segmentation 136Figure 69: Microbiology Culture Market, China, Revenue Mix ($m), 2010 137Figure 70: Microbiology Culture Market, China, Segment Contribution (%), 2010 138Figure 71: Microbiology Culture, China, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 139Figure 72: Microbiology Culture, China, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 141Figure 73: Microbiology Analyzers, China, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 143Figure 74: Microbiology Analyzers, China, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 145Figure 75: Microbiology Culture, China, Company share (%), 2010 148Figure 76: Siemens Healthcare, Company Share (%),China In Vitro Diagnostics Market, 2010 150Figure 77: F. Hoffmann-La Roche Ltd., Company Share (%),China In Vitro Diagnostics Market, 2010 151Figure 78: Sysmex Corporation, Company Share (%),China In Vitro Diagnostics Market, 2010 152Figure 79: Abbott Laboratories, Company Share (%),China In Vitro Diagnostics Market, 2010 153Figure 80: Mindray Medical International Limited, Company Share (%),China In Vitro Diagnostics Market, 2010 154Figure 81: Ortho-Clinical Diagnostics Inc., Company Share (%),China In Vitro Diagnostics Market, 2010 155